drugset / Trial / NCT03833128
A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this Phase 1b study is to assess REN001 safety in subjects with fatty acid oxidation disorders.
Timeline
- Start
- 2019-04-04
- Primary completion
- 2022-01-24
- Completion
- 2022-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mavodelpar | Small molecule | — | Oral |